Support Multiple Systems Atrophy (MSA) Research at GUMC
$100,000 in funding will allow Dr. Charbel Moussa and Dr. Fernando Pagan to perform an early phase clinical study testing Nilotinib, an FDA approved cancer drug known to reduce toxic proteins linked to several neurodegenerative diseases including MSA. All funding will support the enrollment of five MSA patients in the study, and allow GUMC to take this ground-breaking research to the next phase.
Charbel Moussa MBBS (MD), PhD is Associate Professor of Neurology at Georgetown University Medical Center with intensive experience and knowledge about memory and movement disorders. He is the Director of the Laboratory for Dementia and Parkinsonism that studies the pathology and treatment of Parkinson and other movement disorders and Alzheimer and related dementia. Dr Moussa's lab is leading research in drug repositioning and the effects of a class of drugs called tyrosine kinase inhibitors in neurodegeneration. Dr. Moussa established GUMC Translational Neurotherapeutics Program (TNP) that executes clinical trials based on drug discovery within his preclinical lab, providing a continuum from basic and pre-clinical research to regulatory science, biomarker studies and phase I and II clinical trials. Dr. Moussa is also Director and Founder of the Lewy Body Dementia Center of Excellence at GUMC and Clinical Research Director of National Parkinson's Foundation Center of Excellence. He is senior author on more than 75 original articles in scientific and medical journals.
Learn more about Dr. Moussa's lab
*Dr. Charbel Moussa is the inventor on a US patent owned by Georgetown University and on other pending US and foreign patent applications for use of nilotinib and other tyrosine kinase inhibitors for the treatment of neurodegenerative diseases.
Recent Press on other Nilotinib studies at GUMC:
Cures Within Reach Funds Huntington's Disease Clinical Trial with Nilotinib at Georgetown (Sept 27, 2018)
Agent Clears Toxic Proteins, Reduces Inflammation and Improves Cognition in Neurodegeneration Models (July 16, 2017)
Georgetown University Licenses Use of Tyrosine Kinase Inhibitors for Treatment of Neurodegenerative Diseases (May 19, 2017)
Georgetown Announces Phase II Clinical Trial Oof Nilotinib for Parkinson’s Disease (Feb 27, 2017)
For more information, please contact:
Alexandra Tauscher
Associate Director of Development
202-687-1436 | Alexandra.Tauscher@georgetown.edu
No updates for this campaign.
Donors
View All Donors